Zura Bio Limited (NASDAQ:ZURA) Short Interest Update

Zura Bio Limited (NASDAQ:ZURA) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 428,400 shares, a decrease of 31.8% from the March 31st total of 628,300 shares. Based on an average daily volume of 295,200 shares, the days-to-cover ratio is currently 1.5 days. Currently, 2.3% of the shares of the company are sold short.

Zura Bio Price Performance

Shares of NASDAQ ZURA opened at $4.41 on Friday. Zura Bio has a 1-year low of $2.00 and a 1-year high of $14.00. The stock’s 50-day moving average is $3.19 and its 200 day moving average is $4.01.

Insider Buying and Selling at Zura Bio

In other Zura Bio news, Director Amit Munshi acquired 159,744 shares of Zura Bio stock in a transaction on Monday, April 22nd. The stock was purchased at an average price of $3.13 per share, for a total transaction of $499,998.72. Following the purchase, the director now directly owns 777,384 shares of the company’s stock, valued at $2,433,211.92. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders acquired 170,926 shares of company stock worth $534,998 in the last quarter. 15.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zura Bio

A number of large investors have recently modified their holdings of ZURA. Armistice Capital LLC lifted its position in Zura Bio by 66.3% in the third quarter. Armistice Capital LLC now owns 1,580,000 shares of the company’s stock valued at $10,428,000 after purchasing an additional 630,000 shares during the last quarter. Silverarc Capital Management LLC lifted its position in Zura Bio by 152.5% in the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock valued at $2,667,000 after purchasing an additional 244,040 shares during the last quarter. Eisler Capital US LLC bought a new stake in Zura Bio in the third quarter valued at approximately $660,000. Bank of New York Mellon Corp bought a new stake in Zura Bio in the third quarter valued at approximately $224,000. Finally, Forefront Analytics LLC bought a new stake in Zura Bio in the third quarter valued at approximately $95,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Oppenheimer reiterated an “outperform” rating and set a $16.00 price target (down previously from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $16.40.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.